← All companies
EXELIXIS, INC.
EXEL - CIK 0000939767
Market cap$13.22 B
Rank#789
SEC filings2,488
EXELIXIS, INC. trades as EXEL and has a market capitalization of $13.22 B, making it the #789 largest US-listed company by market value. In its fiscal 2026 annual report the company posted revenue of $2.32B, up 7.0% from the prior year and net income of $782.60M. This page tracks EXELIXIS, INC. through 2,488 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$2.32BFY 2026
Net income (latest FY)$782.60MFY 2026
Operating cash flow (latest FY)$884.27MFY 2026
Total assets (latest FY)$2.84BFY 2025
Net margin33.7%latest FY
Financial performance
Over the last 10 fiscal years EXELIXIS, INC.'s revenue grew from $191.45M to $2.32B, a compound annual growth rate of 28.3%. Net profit margin expanded from -36.7% to 33.7% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $13.22 B
- Share price (derived)market cap / shares outstanding
- $52.58
- P/E ratio (trailing FY)
- 16.9
- EPS (diluted)FY 2026
- $2.78
- Shares outstandingas of 2026-04-27
- 0.25B
- Total equityas of 2026-04-03
- $1.94B
- Return on equity
- 40.4%
- Cash & equivalentsas of 2026-04-03
- $226.15M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
Recent press releases
- Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types2026-05-21
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types | Exelixis, Inc.
- Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer2026-05-19
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer | Exelixis, Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May2026-05-07
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May | Exelixis, Inc.
- Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update2026-05-05
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update | Exelixis, Inc.
- Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 20262026-05-05
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
Similar companies
The largest companies sharing EXELIXIS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is EXELIXIS, INC.'s market cap?
EXELIXIS, INC. (EXEL) has a market capitalization of $13.22 B as of 2026-06-10, ranking #789 among US-listed companies.
How much revenue does EXELIXIS, INC. make?
EXELIXIS, INC. reported revenue of $2.32B for fiscal year 2026, an increase of 7.0% year over year.
Is EXELIXIS, INC. profitable?
Yes. EXELIXIS, INC. reported net income of $782.60M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.